For the dopaminergic neurons that are especially vulnerable in Parkinson’s disease, a glut of cholesterol may be a death sentence. That’s according to scientists led by Ming Lu and Lei Cao at Nanjing ...
Research animals raised in cool environments live longer, but why is this so? In the October 21 Nature, scientists led by Hyun Ju Lee and David Vilchez at the University of Cologne, Germany, proposed ...
Loss of the growth-control protein tuberin causes tuberous sclerosis, a neurodevelopmental disorder in which kids have astrocytosis and suffer seizures. Do the latter cause the former? To find out, ...
Genes: Plcg2, APP, PSEN1 Modification: Plcg2: Knock-In; APP: Transgenic; PSEN1: Transgenic Disease Relevance: Alzheimer's Disease Strain Name: N/A Genetic Background ...
Genome-wide association studies have helped identify more than 90 loci that affect a person’s chance of getting Alzheimer’s disease, but these common variants still leave a portion of disease ...
As part of the mammalian innate immune response, the complement system evolved to fight off foreign microbes, and it also helps the brain stave off amyloid plaques. But are all proteins in this ...
Digging deeper into the genetic causes of Alzheimer’s disease, some scientists are studying epigenetic regulation. In the October 12 Nature Aging, a group led by Jinying Zhao at the University of ...
News Bad Origami: Misfolded SOD1 in Living Color 30 Jan 2009 Secretion of SOD1 Mutant Proteins Tied to ALS 23 Dec 2005 Motoneuron Mitochondria: Preferred Destination For Mutant SOD1 12 Jul 2004 The ...
It has been clear for a while that anti-amyloid antibodies can sweep plaque from the brain, but until now the question of whether this slows cognitive decline has remained hotly contended. Despite ...
In a watershed moment for the field, the U.S. Food and Drug Administration today approved the first Alzheimer’s treatment that tackles the underlying disease pathology. Biogen and Eisai’s anti-amyloid ...
The Alzheimer’s field was rocked this week by allegations against Sylvain Lesné at the University of Minnesota, Minneapolis. Lesné stands accused of manipulating data images in multiple papers, ...
In Phase 3, HMTM failed to meet co-primary endpoints. Subgroup analysis of an open-label extension suggests benefit in people with MCI. In that subgroup, half as many people transitioned to AD. HMTM ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results